---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-23-000457"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T10:39:42.039147+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioVie presents blinded Phase 3 NE3107 data at CTAD; cognitive, biomarker improvements observed

## Summary
- Blinded data (n=322) show statistically significant population changes from baseline on ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, ADL.
- Apparent reduction in amyloid burden: 36.5% of PrecivityAD-positive patients reverted to negative after 30 weeks.
- Significant increases in insulin and beta cell function (HOMA2-%B +13.5%, p<0.0001) without hypoglycemia.
- FDG-PET SUVRs increased in 10 of 21 sub-study patients, suggesting reduced amyloid burden.
- Company expects unblinded topline data in late November or early December 2023.

## SEC filing metadata
- accession: 0001520138-23-000457
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013823000457/0001520138-23-000457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013823000457/bivi-20231025_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-23-000457
- JSON: https://secwatch.observer/filing/0001520138-23-000457.json
- Plain text: https://secwatch.observer/filing/0001520138-23-000457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.